These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31764045)

  • 1. New Antibiotic for Community-Acquired Bacterial Pneumonia.
    Aschenbrenner DS
    Am J Nurs; 2019 Dec; 119(12):20-21. PubMed ID: 31764045
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin.
    Rodvold KA
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii2-iii4. PubMed ID: 30949709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
    Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
    Perry W; Golan Y
    Future Microbiol; 2019 Jul; 14():927-939. PubMed ID: 31333062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia.
    Felix TM; Karpa K
    Am Fam Physician; 2020 Sep; 102(6):373-374. PubMed ID: 32931220
    [No Abstract]   [Full Text] [Related]  

  • 8. An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
    Falcó V; Burgos J; Almirante B
    Expert Opin Pharmacother; 2020 Apr; 21(6):629-636. PubMed ID: 31958020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lefamulin for Treating Community-acquired Bacterial Pneumonia in Adult Patients Aged <65 Years.
    Tang HJ; Lai CC
    Clin Infect Dis; 2020 Sep; 71(6):1582. PubMed ID: 31822903
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing.
    Wicha WW; Prince WT; Lell C; Heilmayer W; Gelone SP
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii19-iii26. PubMed ID: 30949704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
    Chahine EB; Sucher AJ
    Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lefamulin (Xenleta) for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865
    [No Abstract]   [Full Text] [Related]  

  • 14. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
    Watkins RR; File TM
    Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
    Lee YR; Jacobs KL
    Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
    Paukner S; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Yu K
    Future Microbiol; 2022 Apr; 17(6):397-410. PubMed ID: 35285291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
    Esposito S; Fiore M
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
    [No Abstract]   [Full Text] [Related]  

  • 20. In community-acquired bacterial pneumonia, lefamulin was noninferior to moxifloxacin at 96 h after the first dose.
    Powell D; Donato A
    Ann Intern Med; 2020 Feb; 172(4):JC22. PubMed ID: 32066155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.